Inhibition of HMGB1 Overcomes Resistance to Radiation and Chemotherapy in Nasopharyngeal Carcinoma
Overview
Affiliations
Objective: This study aimed to investigate the effect of high mobility group protein B1 (HMGB1) on chemoresistance and radioresistance in nasopharyngeal carcinoma (NPC).
Materials And Methods: HMGB1-knockout HK1 cell lines were generated using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system. Western blotting was used to evaluate the protein expression level of HMGB1. DNA repair efficiency of non-homologous end joining (NHEJ) and homologous recombination (HR) was monitored through NHEJ and HR reporter assay. Cellular protein-protein interaction between HMGB1 and NHEJ apparatus was determined by immunoprecipitation. Direct protein-protein interaction was examined by affinity capture assay with purified protein. Protein-DNA binding was evaluated by chromatin fractionation assay. Cell viability assay was employed to measure cell sensitivity to ionizing radiation (IR) or cisplatin.
Results: HMGB1-knockout NPC cells showed significant decrease in NHEJ efficiency. HMGB1 immunoprecipitated NHEJ key factors in NPC cells and promoted DNA-binding activity of Ku70. Mutational analysis revealed that serine 155 of Ku70 was required for its direct interaction with HMGB1. HMGB1 was highly expressed in radio- and chemoresistant NPC cells. Deficiency of HMGB1 sensitized wild-type (WT) and resistant NPC cells to IR and cisplatin. Glycyrrhizin, which is HMGB1 inhibitor, impaired DNA binding of HMGB1 and exhibited excellent synergy with IR and cisplatin.
Conclusion: HMGB1 promotes NHEJ via interaction with Ku70 resulting in resistance to IR and cisplatin. Inhibition of HMGB1 by glycyrrhizin is a potential therapeutic regimen to treat cisplatin and IR resistant NPC patients.
Yang M, Ke Z, Wang D Open Life Sci. 2024; 19(1):20220975.
PMID: 39479349 PMC: 11524390. DOI: 10.1515/biol-2022-0975.
Han Y, Sheng W, Liu X, Liu H, Jia X, Li H Sci Rep. 2024; 14(1):24948.
PMID: 39438689 PMC: 11496679. DOI: 10.1038/s41598-024-76155-w.
Methylation of is a synthetic lethal marker for ATR/CHK1 inhibitors in pancreatic cancer.
Liu F, Gao A, Zhang M, Li Y, Zhang F, Herman J J Transl Int Med. 2024; 12(3):274-287.
PMID: 39081276 PMC: 11284899. DOI: 10.2478/jtim-2023-0128.
The role of lncRNA NEAT1 in human cancer chemoresistance.
Long F, Li X, Pan J, Ye H, Di C, Huang Y Cancer Cell Int. 2024; 24(1):236.
PMID: 38970092 PMC: 11227196. DOI: 10.1186/s12935-024-03426-x.
Multiple functions of HMGB1 in cancer.
Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B Front Oncol. 2024; 14:1384109.
PMID: 38725632 PMC: 11079206. DOI: 10.3389/fonc.2024.1384109.